Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal antiinflammatory activity

Kecskés, Ambrus; Heger-Mahn, Doris; Kuhlmann, René; Lange, L

doi:10.1016/0190-9622(93)70224-h

Cited by 34 publications

(32 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Quantitative differenees for the more recently available GC molecules, as studied here, have also been reported when murine myelomonocytic cells were studied [6]. However, in clinical studies, differences in potency between several of these molecules could not be detected [16][17][18], This under lines the complex dependence of GC action on the cell type studied.…”

Section: Glucocorticoids and Cytokinesmentioning

confidence: 55%

Glucocorticoid-lnduced Modulation of Cytokine Secretion from Normal and Leukemic Human Myelomonocytic Cells

Welker

Lippert²,

Nürnberg³

et al. 1996

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Since glucocorticoid effects on inflammatory processes may be mediated via modulation of cytokine release, different types of myelomonocytic cells were stimulated in vitro with lipopolysaccharide (50 ng/ml) or phorbol myristate acetate (25 ng/ml) plus the ionophore A23187, 2 × 10^––7M, and release of interleukin (IL)-1β IL-8 and tumor necrosis factor (TNF)-α was measured after 24 h by ELISA. Peripheral blood mononuclear cells from two allergic and two normal human donors released similarly large quantities of IL-8 and lower amounts of IL-1β and TNF-α. This also held for myelomonocytic cell lines, with THP-1 cells being most active, followed by U-937 and HL-60 cells. All potent glucocorticoids studied caused a dose-dependent inhibition of cytokine release from donor cells, being most marked for IL-1β and lowest for IL-8. Inhibition of cytokine release was also noted with U-937 cells, with clear differences in potency between the glucocorticoids, whereas release was enhanced in all experiments with THP-1 cells. These results were confirmed with Northern blot analysis. Modulating effects of glucocorticoids on cytokine release are thus complex, and are particularly dependent on the cell type studied.

show abstract

Section: Glucocorticoids and Cytokinesmentioning

confidence: 55%

Glucocorticoid-lnduced Modulation of Cytokine Secretion from Normal and Leukemic Human Myelomonocytic Cells

Welker

Lippert²,

Nürnberg³

et al. 1996

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…In another study 16 g/day mometasone furoate 0.1% ointment applied with occlusion for 11 h/day for 5 days was found to produce a significant decrease in plasma cortisol levels, which was greater than that observed for hydrocortisone butyrate 0.1% 10. Although some decreases in serum cortisol levels were observed in these studies, no symptoms of hypothalamic‐pituitary‐adrenal axis suppression such as fatigue, anorexia, nausea, vomiting or weight loss, was observed in any of the volunteers 5, 8, 9, 10. In further clinical studies in patients with psoriasis,11 adult patients with atopic dermatitis12 children with atopic dermatitis,13, 14 and in adults with various other dermatoses,2 mometasone furoate 0.1% cream applied once daily for up to 12 weeks was not associated with any significant change in mean cortisol levels from baseline.…”

Section: Clinical Safetymentioning

confidence: 60%

“…A decrease in serum cortisol levels was found when 30 g/day mometasone furoate 0.1% ointment was applied to 60% of the body surface with occlusion for 22 h/day for 5 days. However, this decrease was found to be equivalent to that observed for methylprednisolone aceponate 0.1% ointment 9. In another study 16 g/day mometasone furoate 0.1% ointment applied with occlusion for 11 h/day for 5 days was found to produce a significant decrease in plasma cortisol levels, which was greater than that observed for hydrocortisone butyrate 0.1% 10.…”

Section: Clinical Safetymentioning

confidence: 74%

“…Further clinical trials of up to 6 weeks in healthy adult volunteers15, 16, 17 and patients with psoriasis18 have found the atrophogenic potential of mometasone furoate 0.1% ointment or cream to be low. However, in two studies, mometasone furoate 0.1% ointment used for 6 weeks with occlusion in healthy adult volunteers was associated with a significantly greater incidence and severity of skin atrophy and telangiectasia than methylprednisolone aceponate 0.1% ointment9 and prednicarbate 0.1% ointment,1 but it was not as pronounced as it was for betamethasone valerate 0.1% ointment 1…”

Section: Clinical Safetymentioning

confidence: 94%

See 1 more Smart Citation

Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids

Spada¹,

Barnes²,

Greive³

2018

Aust J Dermatology

View full text Add to dashboard Cite

Derivatives of hydrocortisone, such as mometasone furoate, a (2′) furoate‐17 ester with chlorine substitutions at positions 9 and 21, have been designed to improve efficacy and reduce the incidence of adverse effects. An extensive literature search of MEDLINE, Embase and other databases was conducted to review the safety and efficacy of various formulations of topical mometasone furoate. Mometasone furoate exhibits high potency with greater anti‐inflammatory activity and a longer duration of action than betamethasone. In clinical trials, mometasone furoate shows comparable or significantly better efficacy, depending on the comparator, in all indications studied in both adults and children. It is well tolerated with only transient, mild to moderate local adverse effects. It is characterised by low systemic availability due to its high lipophilicity, low percutaneous absorption and rapid hepatic biotransformation, and consequently has no significant effect on the hypothalamic‐pituitary‐adrenal axis. The molecular biotransformation of mometasone furoate in the skin results in a lower affinity with dermal cells than epidermal cells, which contributes to its low atrophogenicity. Sensitisation to mometasone furoate is low. Overall, mometasone furoate is a highly efficacious potent corticosteroid with a low risk of both local and systemic adverse effects.

show abstract

“…Some of the local side effects are skin atrophy, rosacea, and corticoid acne, while the major systemic side effects are hypothalamic-pituitary-adrenal-axis suppression along with diabetes mellitus and hypertension [1,[7][8][9]. Mometasone furoate (MF) is a potent steroid (according to the European Union classification system) with relatively low risk of systemic side effects [1].…”

Section: Introductionmentioning

confidence: 99%

Topical Administration of Mometasone Furoate - A Combined Impedance Spectroscopy and In Vitro Drug Diffusion Study

Runnsjö¹

2015

JAPLR

View full text Add to dashboard Cite

Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal antiinflammatory activity

Cited by 34 publications

References 4 publications

Glucocorticoid-lnduced Modulation of Cytokine Secretion from Normal and Leukemic Human Myelomonocytic Cells

Glucocorticoid-lnduced Modulation of Cytokine Secretion from Normal and Leukemic Human Myelomonocytic Cells

Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids

Topical Administration of Mometasone Furoate - A Combined Impedance Spectroscopy and In Vitro Drug Diffusion Study

Contact Info

Product

Resources

About